New York City, NY, United States
New York City, NY, United States

Time filter

Source Type

NEW YORK, May 11, 2017 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases, today announced the appointment of the Honorable Mike Ferguson as a director and Chairman of the Board following the resignation of Ira Greenstein from the Company’s Board of Directors. “We are honored to have Mike Ferguson join our Board of Directors as our new chairman and believe his experience as a former member of Congress, public policy expert and public health advocate will be invaluable to our Company,” stated Dr. Jason Slakter, CEO.  “Mike has a unique understanding of the importance of medical innovation in our society and has been a tireless advocate for public policy reforms to make new medical treatments more available and affordable.  We welcome his guidance and counsel.   We also wish to thank Ira Greenstein for his many contributions to our Company during his decade of service as the Chairman of our Board of Directors, and wish him all the best in his future endeavors.” “This is an exciting point in the development of Ohr’s lead candidate, Squalamine, and I am pleased to be named Chairman of the Board during this important time,” said Mr. Ferguson.  “Squalamine is an innovative product which has the potential to set a new standard of care for the many patients afflicted with wet AMD. I look forward to working closely with the Ohr team.” The Honorable Mike Ferguson is Senior Advisor and Leader of the Federal Policy Team at Baker Hostetler, one of the nation’s largest law firms, and is a member of the Board of Directors of NanoVibronix Inc.  He served for nearly a decade in the House of Representatives and was a leader on a number of key healthcare and financial services policy initiatives to remove regulatory roadblocks to innovation.  As Vice Chairman of the House health subcommittee, he led policy reforms including the creation of the Medicare Part D prescription drug benefit and pharmaceutical and medical device user fee reauthorizations.  He also authored and shepherded passage of the Lifespan Respite Care Act of 2006, which champions pioneering healthcare policies that improve treatment options for patients. After retiring from Congress, Mr. Ferguson founded Ferguson Strategies, a government affairs and public policy consulting firm that served a wide range of clients, including Fortune 500 companies and start-up firms.  Among his many honors and community services, he is currently Chairman of the Board of Commissioners of the New Jersey Sports and Exhibition Authority, a senior fellow at the Center for Medicine in the Public Interest and a board member of the Independent College Fund of New Jersey.  Mr. Ferguson received a B.A. in government from the University of Notre Dame and a Master of Public Policy degree from Georgetown University. About Ohr Pharmaceutical, Inc.  Ohr Pharmaceutical, Inc. (OHRP) is a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases. The company's lead drug candidate, Squalamine lactate ophthalmic solution, 0.2% (also known as OHR-102), is currently being studied using an eye drop formulation in an ongoing clinical trial for the treatment of the wet form of age-related macular degeneration.  In addition, Ohr has a sustained-release micro fabricated micro-particle ocular drug delivery platform technology. Additional information on the company may be found at www.ohrpharmaceutical.com. Safe-Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made only as the date thereof, and we undertake no obligation to update or revise the forward-looking statement whether as a result of new information, future events or otherwise. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to raise sufficient funds to perform and conclude clinical trials, the financial resources available to us, the ability to negotiate and conclude a strategic partnership, the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments, and general economic conditions. Shareholders and prospective investors are cautioned that no assurance of the efficacy of pharmaceutical products can be claimed or assured until final testing; and no assurance or warranty can be made that the FDA will approve final testing or marketing of any pharmaceutical product. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition.


NEW YORK, May 11, 2017 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases, today announced the appointment of the Honorable Mike Ferguson as a director and Chairman of the Board following the resignation of Ira Greenstein from the Company’s Board of Directors. “We are honored to have Mike Ferguson join our Board of Directors as our new chairman and believe his experience as a former member of Congress, public policy expert and public health advocate will be invaluable to our Company,” stated Dr. Jason Slakter, CEO.  “Mike has a unique understanding of the importance of medical innovation in our society and has been a tireless advocate for public policy reforms to make new medical treatments more available and affordable.  We welcome his guidance and counsel.   We also wish to thank Ira Greenstein for his many contributions to our Company during his decade of service as the Chairman of our Board of Directors, and wish him all the best in his future endeavors.” “This is an exciting point in the development of Ohr’s lead candidate, Squalamine, and I am pleased to be named Chairman of the Board during this important time,” said Mr. Ferguson.  “Squalamine is an innovative product which has the potential to set a new standard of care for the many patients afflicted with wet AMD. I look forward to working closely with the Ohr team.” The Honorable Mike Ferguson is Senior Advisor and Leader of the Federal Policy Team at Baker Hostetler, one of the nation’s largest law firms, and is a member of the Board of Directors of NanoVibronix Inc.  He served for nearly a decade in the House of Representatives and was a leader on a number of key healthcare and financial services policy initiatives to remove regulatory roadblocks to innovation.  As Vice Chairman of the House health subcommittee, he led policy reforms including the creation of the Medicare Part D prescription drug benefit and pharmaceutical and medical device user fee reauthorizations.  He also authored and shepherded passage of the Lifespan Respite Care Act of 2006, which champions pioneering healthcare policies that improve treatment options for patients. After retiring from Congress, Mr. Ferguson founded Ferguson Strategies, a government affairs and public policy consulting firm that served a wide range of clients, including Fortune 500 companies and start-up firms.  Among his many honors and community services, he is currently Chairman of the Board of Commissioners of the New Jersey Sports and Exhibition Authority, a senior fellow at the Center for Medicine in the Public Interest and a board member of the Independent College Fund of New Jersey.  Mr. Ferguson received a B.A. in government from the University of Notre Dame and a Master of Public Policy degree from Georgetown University. About Ohr Pharmaceutical, Inc.  Ohr Pharmaceutical, Inc. (OHRP) is a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases. The company's lead drug candidate, Squalamine lactate ophthalmic solution, 0.2% (also known as OHR-102), is currently being studied using an eye drop formulation in an ongoing clinical trial for the treatment of the wet form of age-related macular degeneration.  In addition, Ohr has a sustained-release micro fabricated micro-particle ocular drug delivery platform technology. Additional information on the company may be found at www.ohrpharmaceutical.com. Safe-Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made only as the date thereof, and we undertake no obligation to update or revise the forward-looking statement whether as a result of new information, future events or otherwise. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to raise sufficient funds to perform and conclude clinical trials, the financial resources available to us, the ability to negotiate and conclude a strategic partnership, the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments, and general economic conditions. Shareholders and prospective investors are cautioned that no assurance of the efficacy of pharmaceutical products can be claimed or assured until final testing; and no assurance or warranty can be made that the FDA will approve final testing or marketing of any pharmaceutical product. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition.


NEW YORK, May 11, 2017 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases, today announced the appointment of the Honorable Mike Ferguson as a director and Chairman of the Board following the resignation of Ira Greenstein from the Company’s Board of Directors. “We are honored to have Mike Ferguson join our Board of Directors as our new chairman and believe his experience as a former member of Congress, public policy expert and public health advocate will be invaluable to our Company,” stated Dr. Jason Slakter, CEO.  “Mike has a unique understanding of the importance of medical innovation in our society and has been a tireless advocate for public policy reforms to make new medical treatments more available and affordable.  We welcome his guidance and counsel.   We also wish to thank Ira Greenstein for his many contributions to our Company during his decade of service as the Chairman of our Board of Directors, and wish him all the best in his future endeavors.” “This is an exciting point in the development of Ohr’s lead candidate, Squalamine, and I am pleased to be named Chairman of the Board during this important time,” said Mr. Ferguson.  “Squalamine is an innovative product which has the potential to set a new standard of care for the many patients afflicted with wet AMD. I look forward to working closely with the Ohr team.” The Honorable Mike Ferguson is Senior Advisor and Leader of the Federal Policy Team at Baker Hostetler, one of the nation’s largest law firms, and is a member of the Board of Directors of NanoVibronix Inc.  He served for nearly a decade in the House of Representatives and was a leader on a number of key healthcare and financial services policy initiatives to remove regulatory roadblocks to innovation.  As Vice Chairman of the House health subcommittee, he led policy reforms including the creation of the Medicare Part D prescription drug benefit and pharmaceutical and medical device user fee reauthorizations.  He also authored and shepherded passage of the Lifespan Respite Care Act of 2006, which champions pioneering healthcare policies that improve treatment options for patients. After retiring from Congress, Mr. Ferguson founded Ferguson Strategies, a government affairs and public policy consulting firm that served a wide range of clients, including Fortune 500 companies and start-up firms.  Among his many honors and community services, he is currently Chairman of the Board of Commissioners of the New Jersey Sports and Exhibition Authority, a senior fellow at the Center for Medicine in the Public Interest and a board member of the Independent College Fund of New Jersey.  Mr. Ferguson received a B.A. in government from the University of Notre Dame and a Master of Public Policy degree from Georgetown University. About Ohr Pharmaceutical, Inc.  Ohr Pharmaceutical, Inc. (OHRP) is a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases. The company's lead drug candidate, Squalamine lactate ophthalmic solution, 0.2% (also known as OHR-102), is currently being studied using an eye drop formulation in an ongoing clinical trial for the treatment of the wet form of age-related macular degeneration.  In addition, Ohr has a sustained-release micro fabricated micro-particle ocular drug delivery platform technology. Additional information on the company may be found at www.ohrpharmaceutical.com. Safe-Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made only as the date thereof, and we undertake no obligation to update or revise the forward-looking statement whether as a result of new information, future events or otherwise. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to raise sufficient funds to perform and conclude clinical trials, the financial resources available to us, the ability to negotiate and conclude a strategic partnership, the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments, and general economic conditions. Shareholders and prospective investors are cautioned that no assurance of the efficacy of pharmaceutical products can be claimed or assured until final testing; and no assurance or warranty can be made that the FDA will approve final testing or marketing of any pharmaceutical product. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition.


NEW YORK, May 11, 2017 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases, today announced the appointment of the Honorable Mike Ferguson as a director and Chairman of the Board following the resignation of Ira Greenstein from the Company’s Board of Directors. “We are honored to have Mike Ferguson join our Board of Directors as our new chairman and believe his experience as a former member of Congress, public policy expert and public health advocate will be invaluable to our Company,” stated Dr. Jason Slakter, CEO.  “Mike has a unique understanding of the importance of medical innovation in our society and has been a tireless advocate for public policy reforms to make new medical treatments more available and affordable.  We welcome his guidance and counsel.   We also wish to thank Ira Greenstein for his many contributions to our Company during his decade of service as the Chairman of our Board of Directors, and wish him all the best in his future endeavors.” “This is an exciting point in the development of Ohr’s lead candidate, Squalamine, and I am pleased to be named Chairman of the Board during this important time,” said Mr. Ferguson.  “Squalamine is an innovative product which has the potential to set a new standard of care for the many patients afflicted with wet AMD. I look forward to working closely with the Ohr team.” The Honorable Mike Ferguson is Senior Advisor and Leader of the Federal Policy Team at Baker Hostetler, one of the nation’s largest law firms, and is a member of the Board of Directors of NanoVibronix Inc.  He served for nearly a decade in the House of Representatives and was a leader on a number of key healthcare and financial services policy initiatives to remove regulatory roadblocks to innovation.  As Vice Chairman of the House health subcommittee, he led policy reforms including the creation of the Medicare Part D prescription drug benefit and pharmaceutical and medical device user fee reauthorizations.  He also authored and shepherded passage of the Lifespan Respite Care Act of 2006, which champions pioneering healthcare policies that improve treatment options for patients. After retiring from Congress, Mr. Ferguson founded Ferguson Strategies, a government affairs and public policy consulting firm that served a wide range of clients, including Fortune 500 companies and start-up firms.  Among his many honors and community services, he is currently Chairman of the Board of Commissioners of the New Jersey Sports and Exhibition Authority, a senior fellow at the Center for Medicine in the Public Interest and a board member of the Independent College Fund of New Jersey.  Mr. Ferguson received a B.A. in government from the University of Notre Dame and a Master of Public Policy degree from Georgetown University. About Ohr Pharmaceutical, Inc.  Ohr Pharmaceutical, Inc. (OHRP) is a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases. The company's lead drug candidate, Squalamine lactate ophthalmic solution, 0.2% (also known as OHR-102), is currently being studied using an eye drop formulation in an ongoing clinical trial for the treatment of the wet form of age-related macular degeneration.  In addition, Ohr has a sustained-release micro fabricated micro-particle ocular drug delivery platform technology. Additional information on the company may be found at www.ohrpharmaceutical.com. Safe-Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made only as the date thereof, and we undertake no obligation to update or revise the forward-looking statement whether as a result of new information, future events or otherwise. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to raise sufficient funds to perform and conclude clinical trials, the financial resources available to us, the ability to negotiate and conclude a strategic partnership, the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments, and general economic conditions. Shareholders and prospective investors are cautioned that no assurance of the efficacy of pharmaceutical products can be claimed or assured until final testing; and no assurance or warranty can be made that the FDA will approve final testing or marketing of any pharmaceutical product. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition.


NEW YORK, May 11, 2017 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases, today announced the appointment of the Honorable Mike Ferguson as a director and Chairman of the Board following the resignation of Ira Greenstein from the Company’s Board of Directors. “We are honored to have Mike Ferguson join our Board of Directors as our new chairman and believe his experience as a former member of Congress, public policy expert and public health advocate will be invaluable to our Company,” stated Dr. Jason Slakter, CEO.  “Mike has a unique understanding of the importance of medical innovation in our society and has been a tireless advocate for public policy reforms to make new medical treatments more available and affordable.  We welcome his guidance and counsel.   We also wish to thank Ira Greenstein for his many contributions to our Company during his decade of service as the Chairman of our Board of Directors, and wish him all the best in his future endeavors.” “This is an exciting point in the development of Ohr’s lead candidate, Squalamine, and I am pleased to be named Chairman of the Board during this important time,” said Mr. Ferguson.  “Squalamine is an innovative product which has the potential to set a new standard of care for the many patients afflicted with wet AMD. I look forward to working closely with the Ohr team.” The Honorable Mike Ferguson is Senior Advisor and Leader of the Federal Policy Team at Baker Hostetler, one of the nation’s largest law firms, and is a member of the Board of Directors of NanoVibronix Inc.  He served for nearly a decade in the House of Representatives and was a leader on a number of key healthcare and financial services policy initiatives to remove regulatory roadblocks to innovation.  As Vice Chairman of the House health subcommittee, he led policy reforms including the creation of the Medicare Part D prescription drug benefit and pharmaceutical and medical device user fee reauthorizations.  He also authored and shepherded passage of the Lifespan Respite Care Act of 2006, which champions pioneering healthcare policies that improve treatment options for patients. After retiring from Congress, Mr. Ferguson founded Ferguson Strategies, a government affairs and public policy consulting firm that served a wide range of clients, including Fortune 500 companies and start-up firms.  Among his many honors and community services, he is currently Chairman of the Board of Commissioners of the New Jersey Sports and Exhibition Authority, a senior fellow at the Center for Medicine in the Public Interest and a board member of the Independent College Fund of New Jersey.  Mr. Ferguson received a B.A. in government from the University of Notre Dame and a Master of Public Policy degree from Georgetown University. About Ohr Pharmaceutical, Inc.  Ohr Pharmaceutical, Inc. (OHRP) is a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases. The company's lead drug candidate, Squalamine lactate ophthalmic solution, 0.2% (also known as OHR-102), is currently being studied using an eye drop formulation in an ongoing clinical trial for the treatment of the wet form of age-related macular degeneration.  In addition, Ohr has a sustained-release micro fabricated micro-particle ocular drug delivery platform technology. Additional information on the company may be found at www.ohrpharmaceutical.com. Safe-Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made only as the date thereof, and we undertake no obligation to update or revise the forward-looking statement whether as a result of new information, future events or otherwise. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to raise sufficient funds to perform and conclude clinical trials, the financial resources available to us, the ability to negotiate and conclude a strategic partnership, the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments, and general economic conditions. Shareholders and prospective investors are cautioned that no assurance of the efficacy of pharmaceutical products can be claimed or assured until final testing; and no assurance or warranty can be made that the FDA will approve final testing or marketing of any pharmaceutical product. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition.


Bielory L.,Rutgers University | Lyons K.,Rutgers University | Goldberg R.,Center for Medicine in the Public Interest
Current Allergy and Asthma Reports | Year: 2012

Allergies are prevalent throughout the United States and impose a substantial quality of life and economic burden. The potential effect of climate change has an impact on allergic disorders through variability of aeroallergens, food allergens and insect-based allergic venoms. Data suggest allergies (ocular and nasal allergies, allergic asthma and sinusitis) have increased in the United States and that there are changes in allergies to stinging insect populations (vespids, apids and fire ants). The cause of this upward trend is unknown, but any climate change may induce augmentation of this trend; the subspecialty of allergy and immunology needs to be keenly aware of potential issues that are projected for the near and not so distant future. © Springer Science+Business Media New York 2012.


Pitts P.J.,Center for Medicine in the Public Interest
Journal of Commercial Biotechnology | Year: 2013

On December 7, 2011, Secretary of Health and Human Services Kathleen Sebelius overruled a decision of the Food and Drug Administration (FDA) on the over-the-counter (OTC) status of emergency contraception. What will be the repercussions of Secretary Sebelius's action? Why is the act itself of far greater long-term significance than the transitory regulatory action it impacts? By reversing an FDA decision, the Secretary has set a dangerous precedent for all-comers to lobby Congress, the Department of Health and Human Services (HHS) and the White House on any and all FDA decisions - directly inserting politics into what must be a scientifically driven process.


Pitts P.J.,Center for Medicine in the Public Interest
Journal of Commercial Biotechnology | Year: 2016

Much ado about pharma freebies to physicians. Much ado about nothing medically and everything politically. A new study published by JAMA Internal Medicine (Pharmaceutical Industry-Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries) makes it sound (as Meagan McArdle has written for Bloomberg), that your doctor is "willing to sell you out for the price of a sandwich." It's not that simple... or true. A valuable takeaway from the new JAMA study should be that wide adoption of Open Payments reporting has led to transparent interactions and value exchanges of education, money and meals between the pharmaceutical industry and prescribers. These data are now available to inform and improve educational efforts to meet the treatment needs of patients using the latest advances in medicine and science. However, such data must be cautiously interpreted with full acknowledgement of study limitations and author bias.


Pitts P.J.,Center for Medicine in the Public Interest
Journal of Commercial Biotechnology | Year: 2015

Let it be said that the spark that ignited the flame was when FDA leadership asked, "Do we know enough about the quality of drugs that are sold in the United States." In 2009, the FDA announced its Safe Use of Drugs Initiative. The theory being that one way to make drugs safer is to ensure that they are used as directed. The main strategy was education and the agency's efforts were (and are) aimed at physicians, nurses, pharmacists, and patients. Earlier this year, the agency announced not just an office, but a Super Office of Pharmaceutical Quality, further underscoring that the FDA operates not under a two-dimensional system of safety and efficacy, but a threedimensional approach that includes quality with a capital (indeed a "super") Q. Since there is no such thing as a safe substandard product, the agency is putting time, resources, and the use of the bully pulpit to go beyond cGMPs, API and excipient sourcing to develop a risk-based approach that includes data gathered from a variety of sources including manufacturing inspections, adverse event reporting, and substandard pharmaceutical events as evidenced in the agency's bioequivalence-driven actions with bupropion in 2012, metoprolol in 2014, and methylphenidate in 2015. So, in many respects, pharmaceutical quality is both a pre and post-licensure endeavor and, like Safe Use, a scientific and educational enterprise that requires close coordination with many stakeholders. And it won't come easily or inexpensively. As Aristotle said that, "Quality is not an act, it is a habit.".


Pitts P.J.,Center for Medicine in the Public Interest
Journal of Commercial Biotechnology | Year: 2015

Healthcare innovation sav es lives, saves money, promotes economic growth, and provides hope for hundreds of millions of people (both patients and care-givers) in the United States and around the world. But innovation isn't easy. There are many roadblocks beyond those of discovery and development. The complicated and conflicting dynamics of politics, perspectives on healthcare economics, of friction between payers, providers, manufacturers, and regulators, the battle for better patient education, and the need for a more forceful and factual debate over the value of innovation all create the need for a more balanced and robust debate. The public policy essays in this paper present some of the key obstructions to maximizing healthcare innovation. The Center for Medicine in the Public Interest is dedicated to addressing these problems head-on and providing practical opportunities to overcome them. Specifically: · The importance of understanding and rewarding incremental innovation. · The price/value debate. Rather than focusing on the short-term costs of healthcare, what are the long-term benefits to both patients and society? We will examine this issue through the lens of the Solvadi debate. · Value-based insurance design. How a more personalized approach to reimbursement matches up well with advances in personalized medicine. · The dynamic and distressing link between co-pays and outcomes and how this relationship must be understood and recalibrated. · The urgent need for transparency in insurance choices within the Affordable Care Act in order to provide the right medicine to the right patient at the right time in a transparent and affordable manner. · How to reach best clinical practice more swiftly through electronic preauthorization and the increasing empowerment of physicians. · Addressing the problem of medication compliance through innovative approaches such as apps and more user-friendly patient education. · How "the story of innovation" can be more clearly and powerfully communicated to various constituencies so that we can narrow the "misperception gap." · Rather than playing the "blame game," how we can advance healthcare innovation by working together to advance the public good.

Loading Center for Medicine in the Public Interest collaborators
Loading Center for Medicine in the Public Interest collaborators